Premium
Anti‐agalactosyl immunoglobulin G antibodies in localized scleroderma
Author(s) -
Mimra Yoshihiro,
Ihn Hronobu,
Jinnin Masatoshi,
Asano Yoshihide,
Yamane Kenichi,
Yazawa N,
Tamaki Kunihiko
Publication year - 2005
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2005.02584.x
Subject(s) - morphea , medicine , localized scleroderma , scleroderma (fungus) , anti nuclear antibody , antibody , immunoglobulin g , rheumatoid factor , connective tissue disease , immunology , autoimmune disease , pathology , autoantibody , fibrosis , biopsy , inoculation
Background Anti‐agalactosyl immunoglobulin G (IgG) antibodies (anti‐AG IgG) have been reported to be detected and correlated with disease activity in some collagen diseases. Method Forty‐seven serum samples from patients with localized scleroderma were examined using an enzyme‐linked immunosorbent assay. Results Anti‐AG IgG were positive in 19% of patients with localized scleroderma. The frequency of anti‐AG IgG in generalized morphea was much higher than that in linear scleroderma or that in morphea. There was a significant correlation between anti‐AG IgG levels and the number of the sclerotic lesions and between anti‐AG IgG levels and the number of involved areas. The levels of anti‐AG IgG were significantly higher in patients with antinuclear antibody, antisingle‐stranded DNA antibody or rheumatoid factor than in those without. Conclusion Anti‐AG IgG can be an indicator of the severity of localized scleroderma.